挽救性放疗为前列腺癌生化复发带来总生存获益:来自国际PROMISE登记研究
基于国际多中心PROMISE登记数据,纳入1410例前列腺切除术后生化复发患者,复发时经血清学与分子影像(PET/CT或PET/MRI)再分期。挽救性放疗与全队列更长总生存相关(HR 0.66,95%CI 0.47-0.93,P=0.019),对分子影像阴性(miT0N0M0)患者获益尤为显著(HR 0.42,95%CI 0.22-0.78,P=0.0061),尤其是PSA≤0.5 ng/mL者。
要点
- 挽救性放疗与生化复发患者更长总生存相关,全队列HR 0.66。
- 分子影像阴性(miT0N0M0)患者获益更显著,HR 0.42。
- PSA≤0.5 ng/mL的分子影像阴性患者从挽救性放疗中获益更明显。
核心结论
- 挽救性放疗改善前列腺癌生化复发患者的总生存,尤其对前列腺特异性膜抗原靶向PET阴性者获益更显著。
研究设计与样本
- 国际多中心PROMISE登记研究(NCT06320223),纳入1410例前列腺切除术后生化复发患者。
- 生化复发时整合血清学标志物与先进分子影像(PET/CT或PET/MRI)进行再分期,评估分子影像TNM分期。
- 中位随访5.2年(四分位距3.8-6.9年)。
主要发现
- 全队列中挽救性放疗与更长总生存相关(HR 0.66,95%CI 0.47-0.93,P=0.019)。
- 接受挽救性放疗者5年和7年生存率分别为95.2%(95%CI 93.6%-96.8%)和90.8%(95%CI 88.1%-93.6%)。
- 未接受挽救性放疗者5年和7年生存率分别为92.1%(95%CI 89.6%-94.7%)和83.8%(95%CI 79.8%-88.1%)。
- 分子影像阴性(miT0N0M0)患者接受挽救性放疗获益显著(HR 0.42,95%CI 0.22-0.78,P=0.0061)。
- 分子影像阴性且PSA≤0.5 ng/mL者获益更明显(P=0.03,log-rank检验)。
关键数值与推荐
- 分子影像阴性(miT0N0M0)患者中381/680例(56.0%)在PET后接受挽救性放疗。
- 分子影像局部区域病变(miT/N+ M0)患者中478/730例(65.0%)在PET后接受挽救性放疗。
临床怎么用
- 前列腺癌术后生化复发患者可考虑在分子影像再分期后行挽救性放疗,以改善总生存。
- 分子影像阴性且PSA≤0.5 ng/mL的患者可能从挽救性放疗中获益更明显。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The impact of salvage radiotherapy (SRT) on overall survival (OS) in patients experiencing biochemical recurrence (BCR) of prostate cancer remains an area of active investigation. The international multicenter PROMISE registry provides a valuable dataset to explore the association between SRT and long-term clinical outcomes in this patient population (NCT06320223). Methods: Comprehensive restaging at the time of BCR was performed by integrating both serologic markers and advanced molecular imaging (PET/CT or PET/MRI), offering an accurate assessment of molecular imaging (mi) TNM stage. Results: In total, 1410 patients experiencing BCR with prior prostatectomy were included. The median follow-up was 5.2 y (interquartile range, 3.8-6.9 y). SRT was administered after PET to 381 of 680 patients (56.0%) with PET-negative disease (miT0N0M0) and to 478 of 730 patients (65.0%) with PET-locoregional disease (miT/N+ M0). SRT was associated with longer OS in the entire cohort (hazard ratio, 0.66; 95% CI, 0.47-0.93; P = 0.019) with 5- and 7-y survival rates of 95.2% (95% CI, 93.6%-96.8%) and 90.8% (95% CI, 88.1%-93.6%), respectively. Without SRT, 5- and 7-y survival rates were 92.1% (95% CI, 89.6%-94.7%) and 83.8% (95% CI, 79.8%-88.1%), respectively. Subgroup analysis found significant benefit for patients with miT0N0M0 disease (hazard ratio, 0.42; 95% CI, 0.22-0.78; P = 0.0061), particularly those with a prostate-specific antigen level of 0.5 ng/mL or lower (P = 0.03, log-rank test). Conclusion: SRT improves OS for patients with BCR, especially those with a negative prostate-specific membrane antigen-targeted PET.
引用
- Guberina N, Karpinski MJ, Guberina M, et al. Salvage Radiotherapy Confers an Overall Survival Advantage in Biochemical Recurrence of Prostate Cancer: Evidence from the International PROMISE Registry. J Nucl Med. 2026. PMID: 42167806. doi:10.2967/jnumed.125.271770
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。